Log in

NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Forecast & News

$104.30
-2.15 (-2.02 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$104.00
Now: $104.30
$107.08
50-Day Range
$98.65
MA: $105.56
$113.76
52-Week Range
$71.85
Now: $104.30
$119.65
Volume449,047 shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio316.06
Dividend YieldN/A
BetaN/A
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:NBIX
CUSIP64125C10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees585
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.


Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings data on Tuesday, February, 4th. The company reported $0.35 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.75 by $0.40. The business earned $244.10 million during the quarter, compared to analyst estimates of $231.54 million. Neurocrine Biosciences's revenue for the quarter was up 85.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.19 EPS. View Neurocrine Biosciences' Earnings History.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Neurocrine Biosciences.

What price target have analysts set for NBIX?

14 analysts have issued 1-year target prices for Neurocrine Biosciences' stock. Their forecasts range from $88.00 to $153.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $117.00 in the next year. This suggests a possible upside of 12.2% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

What is the consensus analysts' recommendation for Neurocrine Biosciences?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

Has Neurocrine Biosciences been receiving favorable news coverage?

News coverage about NBIX stock has been trending somewhat positive on Sunday, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Neurocrine Biosciences.

Are investors shorting Neurocrine Biosciences?

Neurocrine Biosciences saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 4,240,000 shares, a decline of 8.4% from the December 31st total of 4,630,000 shares. Based on an average trading volume of 936,000 shares, the short-interest ratio is presently 4.5 days. Currently, 4.7% of the company's stock are sold short. View Neurocrine Biosciences' Current Options Chain.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Exelixis (EXEL), Twilio (TWLO), Illumina (ILMN) and Sarepta Therapeutics (SRPT).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 61)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 39)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 61)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 54)
  • Dr. Christopher F. O'Brien, Exclusive Consultant (Age 62)

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (3.91%), Pictet Asset Management Ltd. (0.93%), Renaissance Technologies LLC (0.80%), First Trust Advisors LP (0.70%), Victory Capital Management Inc. (0.69%) and Victory Capital Management Inc. (0.68%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View Institutional Ownership Trends for Neurocrine Biosciences.

Which institutional investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Russell Investments Group Ltd., Pictet Asset Management Ltd., Marshall Wace North America L.P., First Trust Advisors LP, Marshall Wace LLP, New York State Common Retirement Fund and Principal Financial Group Inc.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith and Matt Abernethy. View Insider Buying and Selling for Neurocrine Biosciences.

Which institutional investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., Victory Capital Management Inc., Victory Capital Management Inc., Parkman Healthcare Partners LLC, Swiss National Bank, Cubist Systematic Strategies LLC and Mitsubishi UFJ Trust & Banking Corp. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $104.30.


MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  836 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  1,128
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Featured Article: Cost of Debt

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel